脂脉宁胶囊对颈动脉粥样硬化合并原发性高血压患者血压的影响

Influence of Zhimaining capsule (脂脉宁胶囊) on blood pressure of patients with carotid atherosclerosis complicated with primary hypertension

目的：观察脂脉宁胶囊对颈动脉粥样硬化（CAS）合并原发性高血压（EH）患者血压的影响。方法：将31例CA S合并EH患者随机分为两组,观察组（15例）给予脂脉宁胶囊;对照组（16例）给予血脂康。一次性给药后连续观察两组患者用药前及用药后0.5、1、2和3 h的收缩压变化;两组均每日给药3次,连续服药,每日测血压1-2次,观察用药4周内降压药物停减情况。结果：①观察组用药后0.5 h收缩压逐渐下降,2~3 h基本达到谷底;而对照组用药后各时间点收缩压均无明显降低。观察组用药后1、2和3 h收缩压明显低于对照组（P〈0.05或P〈0.01）。②观察组用药1周即有9例患者减量,2周所有患者均有停减,之后停减率增加,减药剂量增大;而对照组前2周无明显变化。4周时观察组已全部减量1/2以上甚至停用,而对照组减量1/2者不足1/3。结论：脂脉宁胶囊有降血压及稳定血压的作用,用于治疗CAS合并EH有效。

Objective： To observe carefully the influence of Zhimaining capsule （脂脉宁胶囊） on blood pressure of patients with carotid atherosclerosis （CAS） complicated with essential hypertension. Methods： Thirty- one CAS patients complicated with hypertension were randomly divided into two groups. One group with 15 patients took Zhimaining capsule; the otlfer 16 patients took Xuezhikang （血脂康） as control group. The changes of systolic blood pressure were observed consecutively before administration and at 0. 5, 1, 2 and 3 hours after a single dose administration. All patients were given the drugs three times per day, and the blood pressures were tested once or twice everyday. The dose changes of drug for hypertension were recorded from the beginning of therapeutic course to the 4 th week. Results： （1）Systolic blood pressure descended gradually after orally taking Zhimaining capsule for0. 5 hours, and about 2 - 3 hours later the drug action approached to its maximum. The drug action differences at 1, 2 and 3 hours were significant compared with the control group （P〈0.05 or P〈0. 01）, while the systolic blood pressure changes of the control group at those three time points were very little. （2）The drug actions of the Zhimaining group were all significant. The therapeutic results indicated that after one -week -therapy with Zhimaining capsule, 9 patients reduced the dose of original western medicine for treatment of hypertension. At the end of the second week, all the patients using Zhimaining capsule stopped or reduced the dose of western medicine. And then, more and more patients could do so. While in control group, there were no obvious dose changes of the original western medicine for hypertension in the first 2 weeks. After 4 weeks＇ therapy, the entire Zhimaining group reduced the dose of western medicine, and more than 50% of patients stopped the drug completely. While in the control group, 4 weeks later there were less than 1/3 of patients whodecreased half of the original dose of western medicine for hypertension. Conclusion. Zhimaining capsule has the action of reducing and stabilizing the blood pressure. It is efficient for the treatment of CAS complicated with essential hypertension.